Allele C-509T in the promoter region of the transforming growth factor β (TGFB1) associated with radiation-induced fibrosis risk of breast cancer in patients with early-stage breast cancer, according to a study published online July 19 JAMA in oncology.
Aaron J.. Grossberg, MD, of the University of MD Cancer Center of Texas in Houston, and colleagues examined the correlation between the allele variants of C-509T in the promoter region TGFB1 and fibrosis, breast cancer three years after radiation therapy in a cohort study were included in the open randomized clinical trial that compared hypofractionated whole breast irradiation (WBI) with conventionally fractionated WBI. Two hundred and eighty-seven women aged 40 years and older with pathologically confirmed stage from 0 to IIA breast cancer who underwent breast conservation surgery, they have been reported and were followed for at least three years.
TGFB1 genotype and three-year data on the toxicity caused by radiation therapy were available for 174 patients, of which 51 percent had at least one copy of the C-509T. Researchers have found that in 13.8% of patients with C-509T and 3.8 per cent of them had fibrosis chest level 2 or above without allelic variant. In the multiparameter assay only factors significantly associated with risk of breast fibrosis, were C-509T and postoperative cosmetic outcomes (odds ratios 4.47 and 7.09 respectively).
"Allele C-509T in TGFB1 is a key factor in breast cancer risk of fibrosis," the authors write. "Evaluation TGFB1 genotype may contribute a personalized approach to solutions with locoregional treatment of breast cancer."
Two authors disclosed financial ties to the pharmaceutical and medical devices.